San Francisco, CA, 2 - 5 December 2019

Schedule

Create your personal agenda –check the favourite icon

Dec 213:00
Conference pass

Tissue multiplex immune-profiling analysis promises and challenges

WORKSHOP A
Dec 213:00
Conference pass

Use of receptor agonists in improving existing adjuvants or designing new novel adjuvants for different animal species

WORKSHOP B
Dec 213:30
Conference pass

Immuno-oncology biomarker strategies for patient selection – An industry perspective

WORKSHOP A
Dec 213:30
Conference pass

Precision adjuvants; tailoring immune activation for next generation vaccines

WORKSHOP B
Dec 214:00
Conference pass

A "next generation" system for analyzing T cell responses and specificities for TB and applicability to cancer

WORKSHOP A
Dec 214:00
Conference pass

Evaluation of Human Vaccines prior Vaccination: Of Hope and Hype

WORKSHOP B
Dec 215:00
Conference pass

Uncovering the dynamics of T cell mediated immunity during CAR T cell therapy through multi-omic analysis: a case in glioblastoma

WORKSHOP A
Dec 215:00
Conference pass

Next generation saponin adjuvants for improved vaccines

WORKSHOP B
Dec 215:30
Conference pass
Dec 215:30
Conference pass

The cGAS-STING Patgadhway as a Target for Enhancing Vaccine Efficacy, Antiviral Therapeutics, and Cancer Immunotherapy

WORKSHOP B
Dec 216:00
Conference pass

Dissecting the biology and the immune microenvironment in colorectal cancer

WORKSHOP A
Dec 216:00
Conference pass

Modulating Systemic Inflammation of Adjuvants While Increasing Efficacy Using Immune Potentiators

WORKSHOP B

Create your personal agenda –check the favourite icon

Dec 308:30
Conference pass

Immunotherapy 2020 and beyond – what are the next frontiers?

Keynotes
  • In the last 10 years ground breaking advances and progress have been made in the treatment of cancer with immunotherapy-based approaches.
  • We have seen approvals of cancer vaccines, multiple single agent and combination checkpoint inhibitor agents in a broad range of tumor types, tissue-agnostic immunotherapy and cellular and gene therapies.
  • These agents are improving survival and providing cures in some cancer patients.
  • Several new immunotherapy advancements, opportunities and challenges are on the horizon.
Dec 308:50
Conference pass

Advances in integrative analysis of single cell sequencing and multiple omics data for a better understanding of response to immunotherapy and vaccination

Keynotes
  • Advances in the development of novel computational methods to understand response to therapy in infectious diseases and cancer
  • Challenges associated with large data volumes and numerous measured variables on statistical power with small sample sizes
  • Use of correlation and mechanistic connections to overcome challenges with high dimensional data
  • Important components of software platforms for data management and analysis and how they can be improved
  • Challenges of missing or incomplete data in multi-omic datasets
Dec 309:45
Conference pass

The use of vaccines and antibodies in biodefense strategies to combat emerging threats

Keynotes
  • The government’s plan to pre-preparedness
  • Funding mechanisms and current vaccine portfolio
  • Product development
  • Operational side of taking a product to the field
Dec 310:30
Conference pass

Morning Networking Break

Keynotes
Meet the Investor Speed Networking: Meet, exchange interests and swap business cards with investors in the biotechnology sector. A great opportunity to maximize your time at the event and meet up to 10 investors in 15mins. Investors include:
Dec 311:30
Conference pass
Dec 311:30
Conference pass

Chair’s Opening Remarks

New Technology
Dec 311:30
Conference pass

Chair’s Opening Remarks

Vaccine Development
Dec 311:40
Conference pass

Development and validation of biomarkers for diagnosis and prediction of response resistance to treatment

Immune Profiling
Dec 311:40
Conference pass

Should each patient’s immune system inform their immunotherapy?

Cancer Immunotherapy
  • ATLAS™, an autologous immune assay that identifies specific immunogenic neoantigens, is more effective at identifying immunogenic CD4 AND CD8 targets than algorithms
  • High variability between patients shows that each individual’s immune system evolves differently throughout their lives
  • Immunosuppressive peptides, identified only through ATLAS, can undercut immunity and compromise immune function
Dec 311:40
Conference pass
Dec 312:10
Conference pass

Intralesional IL12 enhances anti-PD-1 immune response in treatment-refractory solid tumors

Immune Profiling
  • Intro
  • Plasmid DNA electroporation platform
  • KEYNOTE-695 Clinical trial highlights
  • Biomarker data
  • Conclusion
Dec 312:10
Conference pass

An integrated machine-learning approach to improve the prediction of clinically relevant neoantigens

Cancer Immunotherapy
  • We will outline a high performing machine learning approach that predicts naturally presented antigens to the tumor cell surface
  • The predictor, known as the Immuneoprofiler, is integrated with several immune parameters in a deep learning layer
  • We illustrate the application of the Immuneoprofiler to significantly improve the identification of neoantigen targets for personalised cancer immunotherapy
Dec 312:10
Conference pass

RosettaAntibodyDesign - a platform for computational antibody design

New Technology
Dec 312:40
Conference pass

Determinants of clinical response to CAR-T therapy

Immune Profiling
Dec 312:40
Conference pass

Artificial Intelligence to the rescue: towards personalized, neoantigen-targeted immunotherapeutics

Cancer Immunotherapy
Dec 312:40
Conference pass

Introducing a new bioparticle platform; design, polyvalence, production and immunomodulatory potential

New Technology
Dec 312:40
Conference pass

Update on the development and use of a single-dose live oral cholera vaccine

Vaccine Development
Dec 312:55
Conference pass

Development of EcoCRM®, a new GMP CRM197 carrier protein

New Technology
Dec 313:10
Conference pass

Networking lunch and poster session

Keynotes
Innovation & Start up Zone – meet emerging biotechs and discover their innovative platforms and novel technologies in the vaccine & immunotherapy space. Taking place in the exhibition area.Start-up companies include; Meissa Vaccines, Inflammatix, BioGraph 55, Avalia Immunotherapies
Dec 314:10
Conference pass

Reading the immune response: generalizable biomarkers by leveraging heterogeneity across independent cohorts

Immune Profiling
Dec 314:10
Conference pass

A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types

Cancer Immunotherapy
  • Development of new paradigm shifting cancer immune-therapies
  • translational strategies from basic preclinical studies to clinical trials
  • detailed pipeline/ portfolio of validated B-cell peptide vaccines
  • Development of combinatorial immunotherapeutic strategies
Dec 314:10
Conference pass

Targeting highly conserved influenza virus epitopes with self-assembled peptides

New Technology
  • A new vaccine platform is being developed that targets B cell epitopes derived from host and microbial proteins.
  • Peptides synthesized with epitopes from the viral M2e, neuraminidase, and hemagglutinin stem proteins induce protective antibody responses in challenged mice.
  • These results suggest a path forward for the development of a universal influenza vaccine.
Dr Chris Clegg, President, Founder And Chief Scientific Officer, TRIA Bioscience
Dec 314:10
Conference pass

Update on the development and use of a single-dose live oral cholera vaccine

Vaccine Development
Dec 314:25
Conference pass

High yield, high purity cell separation and concentration with an automated microfluidic-based system

New Technology
  • A new vaccine platform is being developed that targets B cell epitopes derived from host and microbial proteins.
  • Peptides synthesized with epitopes from the viral M2e, neuraminidase, and hemagglutinin stem proteins induce protective antibody responses in challenged mice.
  • These results suggest a path forward for the development of a universal influenza vaccine.
Dec 314:40
Conference pass

Decoding cell-free biomarker patterns to optimize the next generation of precision immunotherapies

Immune Profiling
Jimmy Lin, Chief Scientific Officer, Freenome
Dec 314:40
Conference pass

Pfizer’s vaccine immunotherapy combination regimen for cancer

Cancer Immunotherapy
Dec 314:40
Conference pass

Vaccine development in Chikungunya, a severe disease with debilitating long-term effects and global outbreak potential

New Technology
Dec 314:40
Conference pass

Development of a bioconjugate vaccine against E. coli

Vaccine Development
Dec 315:10
Conference pass

Overview of Immune Epitope Database

Immune Profiling
  • Overview of Immune Epitope DatabaseWhat does the IEDB do?
  • How to access data
  • Predictive tools
  • How does this integrate into other databases?
Dec 315:10
Conference pass

Mesenchymal stem cells as a novel approach for optimization of oncolytic virus delivery: from the bench to phase I/II trials

Cancer Immunotherapy
Dec 315:10
Conference pass

Peptide-based checkpoint receptor inhibitors as adjuvants and therapeutics in infectious diseases

New Technology
Dec 315:10
Conference pass

Prophylactic and therapeutic vaccine approach targeting C. difficile infection and relapse

Vaccine Development
Dec 315:25
Conference pass

Supercharging immunotherapy with novel vector technology harnessing the exceptional immunogenicity of arenaviruses

New Technology
Dec 315:40
Conference pass

Susceptible or Immune? A CMV T cell assay accurately predicts patient status

Immune Profiling
  • Cellular immunity is key to controlling many viral infections, particularly in high risk populations.
  • A flow cytometry based, intracellular cytokine detection method has been developed and validated to measure CD4 and CD8 T cell responses to CMV antigen.
  • Clinical studies have demonstrated strong sensitivity, specificity, positive predictive values and negative predictive values for CMV viremia and disease.
Dec 315:40
Conference pass

Stem Cell Delivered Oncolytic Virotherapy – First-in-human Phase I Clinical Trial

Cancer Immunotherapy
Dec 315:40
Conference pass

Toxoid Based Multivalent Vaccine for Methicillin-Resistant Staphylococcus Aureus

Vaccine Development
Dec 315:55
Conference pass

A novel chemistry platform for coupling immunogenic peptides to TLR2-agonist adjuvants to generate fully-synthetic, self-adjuvanting cancer vaccines

New Technology
Dec 316:40
Conference pass

Developing and utilizing positional scanning combinatorial libraries for T-lymphocyte antigen discovery

Immune Profiling
  • General concepts and illustration of positional scanning combinatorial libraries composed of trillions of peptides
  • T cell driven antigen identification approach integrates the screening results of positional scanning libraries and protein databases
  • Examples of the elucidation of the peptide and antigen specificity of T cells with unknown specificity
Dec 316:40
Conference pass

Armed and dangerous against cancer: TGF-beta trap and personalized oncolytic adenoviruses

Cancer Immunotherapy
  • Positive clinical data from first two patients treated with personalized i.e., neoantigen enhanced oncolytic adenoviruses
  • Data from TGF-beta trap virus, which is only months away from a Phase 1 trial, that shows abscopal anticancer activity and evidence of cold-to-hot tumor transformation
  • Biodistribution data from intravenous and intratumoral administration of the TGF-beta trap virus, which demonstrates persistent non-negligible serum levels of the TGF-beta trap
Dec 316:40
Conference pass

Engineering vaccine antigens to recruit CD4 T cell memory for enhanced antibody responses

New Technology
Lenny Moise, Director Of Vaccine Research, EpiVax Inc
Dec 316:40
Conference pass
Dec 317:10
Conference pass

Human in vitro modeling to inform precision vaccines for vulnerable populations

Immune Profiling
Dec 317:10
Conference pass

Mechanism of action of oncolytic virus therapies

Cancer Immunotherapy
  • Oncolytic virus therapy has the potential to combine with checkpoint inhibitors to improve anti-tumor immunity
  • The anti-tumor T cell repertoire is changed post OV treatment
  • Single cell RNA sequencing studies suggest that oncolytic viruses re-shape the intra-tumoral immune compartment
Dec 317:10
Conference pass

A novel hybrid virus-like-particle technology to accelerate the conversion of antigenic epitopes into efficient immunogens deliverable as vaccines

New Technology
Dec 317:10
Conference pass
Dec 317:40
Conference pass

Identification of novel mycobacterial factors involved in virulence and evasion of host immune responses in tuberculosis

Immune Profiling
Dec 317:40
Conference pass

Development of a new oncolytic immunotherapy platform based on herpes simplex virus

Cancer Immunotherapy
Dec 317:40
Conference pass

Unique immunotherapy approach, based on an oncolytic virus non-covalently combined with tumor-specific peptides, for a highly immunogenic and rapidly adaptable tumor vaccination platform.

New Technology
Dec 317:40
Conference pass

Understanding the immunology of syphilis using modern technology to develop a vaccine against this resurgent pathogen

Vaccine Development

Create your personal agenda –check the favourite icon

Dec 408:30
Conference pass

Chair’s Opening Remarks

Vaccine Development
Dec 408:30
Conference pass
Dec 408:30
Conference pass

Chairs Opening Remarks

Engaging T-Cells, Cancer Antibodies, and Combinations
Dec 408:30
Conference pass

Chair’s Opening Remarks

Immunotherapy Bioprocessing, Manufacture & Delivery
Dec 408:40
Conference pass

Mucosal delivery of universal flu vaccine antigens in animal models

Vaccine Development
Dec 408:40
Conference pass

Pre-clinical toxicology considerations for vaccine development

Clinical Development
Dec 408:40
Conference pass

Recurrent Stage 4 Cancer: A patient’s journey and hope for the future

Engaging T-Cells, Cancer Antibodies, and Combinations
Dec 408:40
Conference pass

Opportunities and challenges for integrating delivery technologies into cancer immunotherapy

Immunotherapy Bioprocessing, Manufacture & Delivery
Dec 409:10
Conference pass

Developing a single vaccine to protect against all influenza strains using ground-breaking mathematical models and research

Vaccine Development
Dec 409:10
Conference pass

Novel correlates of protection against pandemic influenza

Clinical Development
Dec 409:10
Conference pass

Targeting soluble TNF to overcome trastuzumab resistance in HER2+ breast cancer

Engaging T-Cells, Cancer Antibodies, and Combinations
    MUC4 expression predicts trastuzumab resistance in HER2+ breast cancerMUC4 expression is driven by soluble TNFNeutralization of sTNF with INB03 prevents trastuzumab resistance in women with MUC4+/HER2+ breast cancer
Dec 409:10
Conference pass

Development of novel antibody-directed nanotherapeutics (ADN) for infectious diseases and cancer

Immunotherapy Bioprocessing, Manufacture & Delivery
Dec 409:40
Conference pass

Protection against Respiratory Syncytial Virus (RSV) by maternal immunization

Vaccine Development
Dec 409:40
Conference pass

The Potential Impact of a Norovirus Vaccine in the U.S.

Clinical Development
Dec 409:40
Conference pass

Development of Bavituxiumab in combination with pembrolizumab for advance gastric or gastroesophageal cancer

Engaging T-Cells, Cancer Antibodies, and Combinations
  • MOA including data on Bavituxiumab overcoming T cell exhaustion
  • Combination preclinical data with CPIs and other IO agents
  • Rationale to support combination with keytruda in Gastric cancer
Dec 409:40
Conference pass

Engineering bispecific IgM antibodies as cancer therapeutics

Immunotherapy Bioprocessing, Manufacture & Delivery
Dec 410:10
Conference pass

A novel live attenuated RSV vaccine

Vaccine Development
Dec 410:10
Conference pass
Dec 410:10
Conference pass

Design & manufacture of next generation biotherapeutics with a scalable biochemical protein synthesis platform

Immunotherapy Bioprocessing, Manufacture & Delivery
  • Introduction to Sutro’s proprietary Cell Free Protein Expression Technology.
  • How the rapid cycle time of the CF reaction allows for high throughput screening of designed structural variants, including incorporation of non-natural amino acids, to enable development of optimal proteins for both function and manufacturability.
  • Demonstration of successful scale up from microliters at bench scale to 1000 liters in a GMP manufacturing environment.
Dec 410:25
Conference pass

High resolution analysis of antibody epitope repertoire dynamics in vaccine design and efficacy characterization

Clinical Development
Dec 411:30
Conference pass

Interactive Roundtables - Click to View

Keynotes
Interactive discussions with like-minded peers tackling the similar challenges in vaccine, antibody and immunotherapy development (Roundtables run twice each for 45mins, select two options)
Flavivirus vaccine – induced immune responses using mouse models
How to increase consumer acceptance of travel vaccine recommendations
Improve patient stratification using recent immune profiling strategies
Influenza vaccination and the diversity paradox
Managing process improvements for vaccines
Managing toxicity in combination immunotherapy
Pamela Munster, Professor, University of California San Francisco
Meet the investor: your questions answered
The road map to NIH’s grant application process. How to find out more about the current programs available
Dr Susan Old, Deputy Director Of The Division Of Extramural Activities, NIAID
Dec 413:10
Conference pass

Networking Lunch and Poster session

Keynotes
Innovation & Start up Zone – hear emerging biotechs present their innovative platforms and novel technologies in the vaccine & immunotherapy space. Taking place in the exhibition area.
Dec 414:30
Conference pass

RSV F and G Sequence Evolution Over the 2016-2019 RSV Seasons in the USA and its Implications in Vaccine and Anti-RSV Drug Development

Vaccine Development
Dec 414:30
Conference pass

Location, Location, Location: How tissue residency influences T cell function and protective capacity

Clinical Development
Dec 414:30
Conference pass

BiTE target identification for solid tumors

Engaging T-Cells, Cancer Antibodies, and Combinations
Dec 414:30
Conference pass

Concept to Clinic : Development of Fc-Containing XmAb® bispecific antibodies for immunotherapy

Immunotherapy Bioprocessing, Manufacture & Delivery
  • Introduction to modular XmAb heterodimeric Fc platform, engineered for efficient development of bispecific antibodies and Fc fusion therapeutics.
  • Highlight important design considerations implemented for development, with summary preclinical and bioprocess data to support the concept
  • A snapshot of available clinical data for lead molecule will be presented – completing the full “Concept to Clinic” path.
  • New enhancements and designs will be discussed that address widening of therapeutic window for these molecules.
Dec 415:00
Conference pass
Dec 415:00
Conference pass

Next generation Pneumococcal bioconjugate vaccine, multivalent Klebsiella pneumoniae and Group B Streptococcus bioconjugate vaccine

Clinical Development
Dec 415:00
Conference pass

Cancer immunotherapy beyond checkpoint inhibition: harnessing the potential of CD40 agonists

Engaging T-Cells, Cancer Antibodies, and Combinations
Dec 415:00
Conference pass

Challenges in the development and clinical manufacturing of personalized neoantigen-based cancer vaccines and T-cell therapy

Immunotherapy Bioprocessing, Manufacture & Delivery
Dec 415:30
Conference pass
Dec 415:30
Conference pass

Preliminary results from an H2 HA-Ferritin vaccine phase I trial

Clinical Development
Dec 415:30
Conference pass

Versamune; a novel T-cell activating immunotherapy platform

Engaging T-Cells, Cancer Antibodies, and Combinations
Versamuneâ (R-DOTAP nanoparticles) works by facilitating several critical immunological mechanisms:
  • Superior in vivo priming of tumor antigens through dendritic cell uptake and destabilization of the endosomal membrane, enabling associated antigens to effectively access the class-I and class-II MHC pathways to prime tumor (HPV)-specific CD8+ and CD4+ T cells.
  • Potent immune activation as a result of dendritic cell maturation, induction of Type 1 interferon and critical chemokines within lymph nodes that promote T cell migration, activation and proliferation within the lymphatics.
  • Significant increase in CD8+ tumor infiltration with lowering of the Treg to CD8+ T cells ratio within the tumor microenvironment, resulting in “de-camouflaging” of tumors.
  • Induction of robust memory T cell responses resulting in protection from tumor re-challenge following treatment with R-DOTAP and HPV-E7 peptides in preclinical animal studies.
  • Systemic bioavailability of <6% associated with a lack of significant cytokine release and non-specific systemic immune activation, resulting in a highly favorable safety profile for use in combination with other I-O agents and approaches.
Dec 415:30
Conference pass

Rapid manufacture and scale-up of off-the-shelf cell therapies

Immunotherapy Bioprocessing, Manufacture & Delivery
Dec 415:45
Conference pass
Dec 416:30
Conference pass

Development of a Chikungunya VLP vaccine

Vaccine Development
Dec 416:30
Conference pass

Challenges and opportunities in designing immuno-oncology trials: A non-profit perspective

Clinical Development
Dec 416:30
Conference pass

Galinpepimut-S: A novel WT1-targeting multivalent heteroclitic epitope immunotherapeutic: Clinical review

Engaging T-Cells, Cancer Antibodies, and Combinations
· WT1 antigen biology· Overview of galinpepimut-S technology· Updates in galinpepimut-S clinical data· Upcoming phase 3 trial
Dec 416:30
Conference pass

Improving autologous CAR-T access and affordability

Immunotherapy Bioprocessing, Manufacture & Delivery
Dec 417:00
Conference pass

A natural killer T (NKT) cell adjuvanting vaccine platform induces liver-resident memory CD8+ T cells that protect against malaria

Vaccine Development
Dec 417:00
Conference pass

Utilizing a Live Modified Vaccinia Ankara Virus to Deliver Tumor Associated Antigen MUC1 on the Surface of Virus Like Particles for Prevention or Treatments of MUC1 Positive Tumors

Clinical Development
Dec 417:00
Conference pass

Developing Antibody-Drug-Conjugates to unique embryonic cancer stem cell targets

Engaging T-Cells, Cancer Antibodies, and Combinations
Dec 417:00
Conference pass

Designing cutting edge ATMP facilities

Immunotherapy Bioprocessing, Manufacture & Delivery
Dec 417:15
Conference pass

Exploiting a successful immunization platform to develop advanced immuno-oncology remedies

Clinical Development
Dec 417:30
Conference pass

Development of single dose vaccines for emerging and re-emerging infectious diseases, preclinical data for Ebola, Marburg, Lassa Fever and Zika as examples

Vaccine Development
Dec 417:30
Conference pass

Development of precision cancer immunotherapies based on Neo-Epitopes selected using a proprietary machine learning based predictive algorithm, Ancer™

Clinical Development
Dec 417:30
Conference pass

Combining Antibody-Drug Conjugates and immunotherapy: mechanistic insights and clinical observations

Engaging T-Cells, Cancer Antibodies, and Combinations

Create your personal agenda –check the favourite icon

Dec 509:00
Conference pass
Dec 509:00
Conference pass
Dec 509:00
Conference pass

Chair’s Opening Remarks

Vaccine Delivery, Bioprocessing & Manufacture
Risat Jannat, Director, Global Vaccines and Biologics Commercialization,, Merck
Dec 509:00
Conference pass
Dec 509:10
Conference pass
Dec 509:10
Conference pass

Unleashing the potential of gene therapy using the non-viral UltraCAR-T platform for hematological and solid tumors

Engineered Cancer Therapies
Dec 509:10
Conference pass

Development and licensure of an Ebola vaccine

Vaccine Delivery, Bioprocessing & Manufacture
Risat Jannat, Director, Global Vaccines and Biologics Commercialization,, Merck
Dec 509:10
Conference pass

Strategies for the discovery and development of Anti-bacterial mAbs: A. Baumannii mAb Case Study

Infectious Disease Antibodies
Dec 509:40
Conference pass

Development of off-the-shelf, allogenic T-cell immunotherapies for cancer and autoimmune diseases

Engineered Cancer Therapies
  • Epstein-Barr virus (EBV) infects B cells and epithelial cells, and is implicated in cancers and autoimmune diseases including post transplant lymphoproliferative disease (PTLD) and multiple sclerosis (MS).
  • Atara has developed an off-the-shelf, allogeneic T-cell platform which enables rapid delivery of a T-cell immunotherapy manufactured in advance and stored in inventory, with each manufactured lot of cells providing therapy for numerous potential patients.
  • tab-cel® (tabelecleucel) is Atara's most advanced T-cell immunotherapy; it is in Phase 3 for patients with EBV+ PTLD, who have failed rituximab or rituximab plus chemotherapy. The Company is also developing allogeneic T-cell immunotherapies targeting EBV antigens for the potential treatment of MS.
  • Atara is developing a mesothelin-targeted autologous CAR T for patients with advanced mesothelioma, and off-the-shelf, allogeneic CAR T immunotherapies using its next generation technologies and EBV T-cell platform.
Dec 509:40
Conference pass

Advances in development of conjugate and multi-component vaccines

Vaccine Delivery, Bioprocessing & Manufacture
  • The past three decades have witnessed the development and commercial licensure of several multivalent conjugate vaccines against several medically important bacterial pathogens, includingHaemophilus influenzaetype b,Streptococcus pneumoniae,Neisseria meningitidis, andSalmonella typhi.
  • The development of these multivalent conjugate vaccines and new multicomponent candidates, currently in clinical trials, comprising additional protein antigens involves a complex strategy due to the varying structural, process and stability requirements posed by several antigens.
  • The continued addition of more and more antigens to these multicomponent vaccines brings new challenges such as immune interference impacting vaccine efficacy.
  • The presentation will address specific development strategies to address some of the challenges associated with advances in conjugate antigens, comprising these multivalent and multicomponent vaccines.
Dec 509:40
Conference pass

Developing DNA encoded monoclonal antibodies and bi-specific T cell engagers for infectious diseases

Infectious Disease Antibodies
Dec 510:10
Conference pass

TCR-mimic antibody redirected T-cell therapy for solid tumors

Engineered Cancer Therapies
Hongbing Zhang, Senior Research Director, Eureka Therapeutics
Dec 510:10
Conference pass

A unique platform for research scale to mid-scale, host-independent biological manufacturing

Vaccine Delivery, Bioprocessing & Manufacture
Dec 510:10
Conference pass

Harnessing Immunity against Ebola Virus Infection

Infectious Disease Antibodies
Dec 510:25
Conference pass

Site’s perspective on frequent issues around vaccine trials

Clinical Development
(Title TBC)
Dec 511:10
Conference pass

Experimental human challenge models used in respiratory track diseases and malaria

Clinical Development
Dec 511:10
Conference pass

Targeting natural neoantigens through adoptive cellular therapies

Engineered Cancer Therapies
Dec 511:10
Conference pass

Living in uncertain times: challenges with accelerated development and deployment of pharmaceutical countermeasures for unanticipated and unmet medical needs

Vaccine Delivery, Bioprocessing & Manufacture
Dec 511:10
Conference pass

Addressing Neglected Infectious Diseases with Monoclonals

Infectious Disease Antibodies
Dec 511:40
Conference pass

Entering phase 3: NanoFlu vaccine for older adults

Clinical Development
Dec 511:40
Conference pass

Identification of novel T-cell receptor targets and specificity profiling of TCRs tested in the clinic to develop safe & effective TCR therapies

Engineered Cancer Therapies
Dec 511:40
Conference pass

Challenges in vaccine manufacture in LMICs

Vaccine Delivery, Bioprocessing & Manufacture
Dec 511:40
Conference pass

Antibody-based therapy to combat Staphylococcus aureus infections

Infectious Disease Antibodies
Dec 512:10
Conference pass

Drug development challenges within immune-oncology and analytical approaches to address them

Clinical Development
Dec 512:10
Conference pass

Immuno-STAT and Neo-STAT – Therapeutic platforms for the selective modulation of antigen-specific T cells

Engineered Cancer Therapies
Dec 512:10
Conference pass

VsmAp™, Adjuvants, and VaxiPatch™ a new complete Influenza Vaccine solution that improves vaccine protection, can to be distributed in the mail, and can be self-administered

Vaccine Delivery, Bioprocessing & Manufacture
  • Verndari offers a completely modern influenza vaccine
  • VsmApTM, (vaccine synthetic membrane antigen presentation)
  • Advanced Adjuvants
  • VaxiPatchTM Delivery – painless and room temperature stability
  • Verndari Vaccination Kit capable of mail distribution
Dec 512:10
Conference pass

Monoclonal antibody development against infectious diseases in pediatric populations

Infectious Disease Antibodies
Dec 512:40
Conference pass

Gamma delta T-cells: A universal, off-the-shelf immune cell therapy to treat cancer and other diseases

Engineered Cancer Therapies
Dec 512:40
Conference pass

Development of a versatile, single-injection vaccine formulation platform that can enhance immune response

Vaccine Delivery, Bioprocessing & Manufacture
Dec 512:40
Conference pass

Antibody-antibiotic conjugates to treat infectious diseases

Infectious Disease Antibodies
Dec 514:10
Conference pass
Dec 514:20
Conference pass

Microbiome and epigenetic imprinting of immune responses to vaccination in humans

Keynotes
Dec 514:50
Conference pass

What will be the impact of moving towards earlier lines of therapy in cancer?

Keynotes
  • Novel diagnostics and early detection initiatives
  • How will this change how we think about resistance?
  • What happens when we reach maximal amount of t-cell responses?
  • If immune capability decreases with subsequent lines of therapy is it a good idea to delay? Will investigational therapies preclude a patient from getting chemo?
  • Modifying the immune system to respond to immunotherapy
  • How does immunotherapy interact with radiation?
  • How will this affect drug candidate pipelines?
Dec 515:50
Conference pass

Public private partnerships in global health – connecting industry assets and researchers

Keynotes
  • The role of WIPO-ReSearch and BVGH (BioVentures for Global Health)
  • Collaboration between Merck and Co and the Walter and Eliza Hall Institute for Medical Research
  • Discovery of new treatments for malaria
last published: 03/Dec/19 04:35 GMT

 
 
 

Contact us

To sponsor or exhibit contact:
Oliver Breed
+44 (0)207 092 1156

oliver.breed@terrapinn.com


To speak:
Lauren Sheppard
+44 (0)207 092 1211

lauren.sheppard@terrapinn.com